The tweet was deleted by the author.
But we saved everything 🙂.
Corbus Pharmaceuticals Holdings, Inc. has provided new insights into the clinical and commercial development path for CRB-701, its key asset targeting second-line oropharyngeal and cervical cancers.
The company highlighted updated results from its ongoing Phase 1/2 clinical trial, offering important clarity on future milestones for CRB-701. CEO Yuval Cohen stated that these data mark a significant point for both clinical progress and potential commercialization strategies. Additional information and clinical details can be accessed through the company’s official release.
Corbus previously announced plans to present updated Phase 1/2 clinical results for CRB-701 at the 2026 ASCO annual meeting. Earlier this year, the company reported its first quarter financial results and corporate update. These developments set recent context for CRB-701’s clinical and commercial trajectory.